EU regulatory and Quality Requirements for Botanical Drugs and Their Implications

European Union regulatory and quality requirements for botanical drugs and their implications for Chinese herbal medicinal products development


Abstract

This paper introduces regulatory pathways and characteristic quality requirements for marketing authorization of herbal medicinal products in the European Union(EU), and the legal status and applications of "European Union list of herbal substances, preparations and combinations" and "European Union herbal monographs". Also introduced are Chinese herbs that have been granted the EU list entry, those with EU herbal monographs, and registered EU traditional herbal medicinal products with Chinese herbs as active ingredients. Special attention is paid to the technical details of three authorized EU herbal medicinal products (Veregen, Sativex and Episalvan) in comparison with Andrographis paniculata extract HMPL-004 that failed the phase Ⅲ clinical trial for ulcerative colitis. The paper further emphasizes the importance of enriching active fractions of herbal extracts and taking regulatory and quality considerations into account in early stage of botanical drug development.


Source: Materia Medica, 31 May 2017, 42(11):2187-2192

Philadelphia, USA | Blainville, Canada | Cambridge, UK | Semengoh, Malaysia | Hangzhou, China